Brief: Zynerba Says Bright Trial Achieved Clinically Meaningful Improvements From Baseline

Zynerba Pharmaceuticals

27/05/2020 13:14

May 27 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O :
    * ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE
RESULTS FROM
EXPLORATORY OPEN LABEL PHASE 2 BRIGHT TRIAL OF ZYGEL IN AUTISM
SPECTRUM DISORDER
    * ZYNERBA - BRIGHT TRIAL ACHIEVED STATISTICALLY SIGNIFICANT
&
CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE
    * ZYNERBA PHARMACEUTICALS INC - SAFETY DATA REINFORCE
EXCELLENT
TOLERABILITY PROFILE OF ZYGEL
    * ZYNERBA PHARMACEUTICALS - ZYGEL WAS VERY WELL TOLERATED, &
SAFETY PROFILE CONSISTENT WITH PREVIOUSLY RELEASED DATA FROM
OTHER ZYGEL CLINICAL TRIALS
    * ZYNERBA PHARMACEUTICALS -18 PATIENTS WHO COMPLETED BRIGHT
TRIAL
HAVE ROLLED INTO OPEN LABEL EXTENSION
    * ZYNERBA PHARMACEUTICALS - THERE WERE NO SEVERE OR SERIOUS
ADVERSE EVENTS REPORTED DURING STUDY

Source text for Eikon:  ID:nGNX5BPvsr 
Further company coverage:  ZYNE.O 

 ((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))